ZA886082B - Pharmaceutically useful polymorphic modification of buspirone - Google Patents

Pharmaceutically useful polymorphic modification of buspirone

Info

Publication number
ZA886082B
ZA886082B ZA886082A ZA886082A ZA886082B ZA 886082 B ZA886082 B ZA 886082B ZA 886082 A ZA886082 A ZA 886082A ZA 886082 A ZA886082 A ZA 886082A ZA 886082 B ZA886082 B ZA 886082B
Authority
ZA
South Africa
Prior art keywords
buspirone
pharmaceutically useful
polymorphic modification
useful polymorphic
modification
Prior art date
Application number
ZA886082A
Other languages
English (en)
Inventor
Jack C Simms
C Simms Jack
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22225222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA886082(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of ZA886082B publication Critical patent/ZA886082B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Body Structure For Vehicles (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
ZA886082A 1987-08-28 1988-08-17 Pharmaceutically useful polymorphic modification of buspirone ZA886082B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/090,984 US5015646A (en) 1987-08-28 1987-08-28 Pharmaceutically useful polymorphic modification of buspirone

Publications (1)

Publication Number Publication Date
ZA886082B true ZA886082B (en) 1989-04-26

Family

ID=22225222

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA886082A ZA886082B (en) 1987-08-28 1988-08-17 Pharmaceutically useful polymorphic modification of buspirone

Country Status (22)

Country Link
US (1) US5015646A (da)
EP (1) EP0304941B1 (da)
JP (1) JP2716740B2 (da)
KR (1) KR970011297B1 (da)
AT (1) ATE101147T1 (da)
AU (1) AU618549B2 (da)
CY (1) CY1785A (da)
DE (1) DE3887598T2 (da)
DK (1) DK170821B1 (da)
ES (1) ES2061576T3 (da)
FI (1) FI883961A (da)
HK (1) HK74494A (da)
HU (1) HU201322B (da)
IE (1) IE63071B1 (da)
IL (1) IL87468A (da)
MY (1) MY104061A (da)
NO (1) NO883805D0 (da)
NZ (1) NZ225896A (da)
OA (1) OA08908A (da)
PT (1) PT88356B (da)
YU (1) YU46962B (da)
ZA (1) ZA886082B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
HU217129B (hu) * 1993-07-16 1999-11-29 EGIS Gyógyszergyár Rt. Eljárás nagy tisztaságú buspiron gyógyászati hatóanyag előállítására
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
RU2198169C3 (ru) 1998-06-19 2017-07-20 Тейдзин Лимитед Полиморфные формы 2-(3-циан-4-изобутилоксифенил)-4-метил-5-тиазолкарбоновой кислоты и способы их получения
US6465255B1 (en) * 1999-01-29 2002-10-15 The Regents Of The University Of California Method for identifying and probing phase transitions in materials
KR100433165B1 (ko) * 2000-10-10 2004-05-27 엔앤비텍 주식회사 가공란의 제조 방법, 상기 방법에 의하여 제조된 가공란,및 가공란을 제조하기 위한 장치
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
SI1750766T1 (sl) 2004-05-11 2013-11-29 Emotional Brain B.V. Farmacevtske formulacije in njihove uporabe pri zdravljenju spolne disfunkcije pri Ĺľenskah
JPWO2006052026A1 (ja) * 2004-11-12 2008-05-29 帝人ファーマ株式会社 ベンズイミダゾール誘導体の酸性塩及びその結晶
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4351939A (en) * 1980-10-16 1982-09-28 Mead Johnson & Company Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen

Also Published As

Publication number Publication date
NO883805D0 (no) 1988-08-25
DK478788D0 (da) 1988-08-26
FI883961A0 (fi) 1988-08-26
CY1785A (en) 1995-10-20
FI883961A (fi) 1989-03-01
YU46962B (sh) 1994-09-09
HU201322B (en) 1990-10-28
IL87468A0 (en) 1989-01-31
EP0304941B1 (en) 1994-02-02
KR970011297B1 (ko) 1997-07-09
JPS6471816A (en) 1989-03-16
PT88356A (pt) 1989-06-30
EP0304941A1 (en) 1989-03-01
PT88356B (pt) 1995-03-31
IL87468A (en) 1992-12-01
IE882528L (en) 1989-02-28
US5015646A (en) 1991-05-14
HK74494A (en) 1994-08-05
DK478788A (da) 1989-03-01
OA08908A (en) 1989-10-31
DE3887598T2 (de) 1994-05-19
DE3887598D1 (de) 1994-03-17
AU618549B2 (en) 1992-01-02
KR890003740A (ko) 1989-04-17
IE63071B1 (en) 1995-03-22
DK170821B1 (da) 1996-01-29
AU2107688A (en) 1989-03-02
HUT47564A (en) 1989-03-28
JP2716740B2 (ja) 1998-02-18
YU161688A (en) 1990-10-31
MY104061A (en) 1993-11-30
ATE101147T1 (de) 1994-02-15
ES2061576T3 (es) 1994-12-16
NZ225896A (en) 1991-04-26

Similar Documents

Publication Publication Date Title
ZA886082B (en) Pharmaceutically useful polymorphic modification of buspirone
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
LTIP919A (en) Drugs and process for preparing thereof
PH31123A (en) Benzimidazole compounds.
HUT43582A (en) Process for production of derivatives of 4,5,6-substituated-n-/substituated phenil/-piramidin-amin and medical compounds containing thereof
EP0397697A4 (en) Quinoline derivatives as antagonists of leukotriene d 4?
IE930392L (en) Method of treating cachexia and certain new compounds for¹use in this method
CS38989A2 (en) Method of phenoxyacetamidoderivative production
IL92898A0 (en) Substituted quinolinecarboxylic acids
ZA887399B (en) 4-aminopyridine derivatives
PL286043A1 (en) Method for manufacturing new proteins
EP0328634A4 (en) Pharmaceutical compositions for the treatment of psoriasis
ZA889110B (en) Method for the treatment of anxiety
YU130089A (en) Process for obtaining nedocromyl calcium compounds
OA09027A (fr) Procédé d'inhibition. d'un virus
HK71495A (en) Process for converting the lower melting polymorphic crystalline form of buspirone hydrochloride into the higher melting form thereof
EP0305181A3 (en) Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
YU48634B (sh) Postupak za dobijanje 6-(supstituisanih aminopropionil) derivata forskolina i jedinjenja koja se dobijaju ovim postupkom
CS53688A2 (en) Method of new substituted 3-phenyl-7h-thiazolo/3,2-b//1,2,4/triazine -7-ons production
PL245246A1 (en) Process for preparing novel derivatives of 6-alpha-methyl-prednisolone
IE831874L (en) Polymorphic forms of a guanidinopyrazole derivative.
ES2080656A1 (es) Acidos de hidroxialquilquinolina fluorados como antagonistas del leucotrieno.
RO91151A2 (ro) Metoda chirurgicala de refacere a defectelor osoase ale humerusului